Centre for Commercialisation of Regenerative Medicine Australia (CCRM)

4 5 BUSINESS VIEW OCEANIA VOLUME 4, ISSUE 7 BUSINESS VIEW OCEANIA VOLUME 4, ISSUE 7 CCRM internationalise Australian activities leading to RM powerhouses.” CEO Silvio Tiziani introduces CCRM Australia as crucial to the continued development of Australia’s RM landscape. “RM is a broad and relatively new field of medicine built on a foundation of stem cell work and research, but also encompasses other disciplines such as tissue engineering, biomanufacturing, cell and gene therapy, etc. The idea is to repair or replace tissues or organs that have been damaged or are deteriorating in the body. At CCRM Australia, we collaborate with industry, science, innovation, and academia to understand what our sector needs, remain up to date with the latest technologies and scientific developments, and to establish a network of investors that will help bring new medicines and therapies to market. We collaborate directly with researchers, start-ups, industry organisations, pharmaceutical companies, and prospective investors to fuel growth across the RM ecosystem.” CCRM Australia operates independently of CCRM Canada, Mr Tiziani says, but works closely with them towards common goals. “CCRM Canada began around a decade ago when the Canadian government recognised the great potential for their extensive RM research network to grow in the commercialisation space. The centre was established as a not-for-profit. It has since been involved in almost one billion Canadian dollars of RM projects in Canada, supported 12 Canadian start-ups, and has developed manufacturing facilities and research laboratories in Toronto. We were approached by the CCRM a little over five years ago at Monash University’s Regenerative Medicine Institute and asked to consider replicating their model in Australia. Since we have found great success in doing so, they would like to establish other CCRM-like initiatives worldwide, to create a global network of CCRM ‘hubs’.” Silvio Tiziani, Chief Executive Officer Dr Chih Wei Teng, Chief Operating Officer The Future of Drug Discovery in Neuroscience The paradigm shift away from traditional animal-based biology to human-based biology drug testing is now powered by both the EU (Resolution 2021/2784) and USA (FDA Modernization Act 2021). Tessara’s RealBrain® Drug Screening Platform is ideally placed to capitalize on the urgent demand for • Physiologically accurate • 3-dimensional • high-throughput • human-based biology drug discovery tools to replace traditional animal tests. See our editorial in this issue to learn more about how Tessara is exploiting its first-mover advantage to accelerate discovery of more effective neural therapies. tessaratherapeutics.com 0.5 mm Image 1: Spherical RealBrain® Micro-Tissues accurately model human brain function due to their functionally mature neural networks. Image 2: Brightfield image stained for Glial cells. Neurites. Nuclei. LEARN MORE 02 01